Predicted to enable histone deacetylase activity. Predicted to be involved in negative regulation of transcription by RNA polymerase II. Predicted to be located in nucleus. Predicted to be part of histone deacetylase complex. Used to study Parkinson's disease. Human ortholog(s) of this gene implicated in several diseases, including cervix uteri carcinoma in situ; chondrodysplasia with platyspondyly, distinctive brachydactyly, hydrocephaly, and microphthalmia; and polycystic liver disease. Is an ortholog of human HDAC6 (histone deacetylase 6).
Inferred by orthology to human genes with DO annotation (HGNC:14064)
Disease_relevance
In elegans, alpha-synuclein (alpha-syn) toxicity, implicated in Parkinson''s disease and other synucleinopathies, is modeled by expressing it from the dopamine transporter (dat-1) gene promotor in transgenic GFP worms, resulting in an age-dependent progressive loss of dopaminergic neurons; using this system, it was seen that the knock-down of specific candidate genes in elegans, that interact with catp-6/ATP13A2, resulted in significant enhancement of alpha-syn-induced dopaminergic neurodegeneration; these catp-6/ATP13A2 interactors include the elegans ortholog of histone deacetylase 6 (hda-6), coagulation factor II (thrombin) receptor (dop-2), AP2 associated kinase 1 (AAK1; sel-5) along with neuropeptide Y receptor Y1 (npr-4), and YIP1 interacting factor homolog A (yif-1).
Map position created from combination of previous interpolated map position (based on known location of sequence) and allele information. Therefore this is not a genetic map position based on recombination frequencies or genetic experiments. This was done on advice of the CGC.